Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 1

2(33.3%)

Phase 3

1(16.7%)

6Total

N/A(3)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07568678Phase 1Recruiting

A Phase 1, Multiple Ascending Dose Study to Evaluate HMS1005 in Participants With Type 2 Diabetes

Role: collaborator

NCT05458219Phase 1Recruiting

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Role: collaborator

NCT05785949Not ApplicableTerminated

Chondro-Gide® Bilayer Collagen Membrane in Knee Cartilage Defect Repair

Role: collaborator

NCT07096050Not ApplicableCompleted

Post Marketing Clinical Follow up Study of HyaleXo

Role: collaborator

NCT02997501Phase 3Completed

T790M Plasma Testing Methodology Comparison and Clinical Validation

Role: collaborator

NCT04187599Not ApplicableRecruiting

Post-market Follow Up Study on Paragon CRT® 100 (Paflufocon D)

Role: collaborator

All 6 trials loaded